目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product & service
1.1.2. Technology
1.1.3. Application
1.1.4. Workflow
1.1.5. End use
1.1.6. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product & service outlook
2.2.2. Technology outlook
2.2.3. Application outlook
2.2.4. Workflow outlook
2.2.5. End use outlook
2.3. Competitive Insights

Chapter 3. India Oncology NGS Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. India Oncology NGS Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape

Chapter 4. India oncology NGS: Product & Service Estimates & Trend Analysis
4.1. India Oncology NGS Market: Key Takeaways
4.2. India Oncology NGS: Movement & Market Share Analysis, 2022 & 2030
4.3. Platforms and Related Products
4.3.1. Platforms and related products market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.1. Panels
4.3.1.2. Panels market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.3. Consumables
4.3.1.4. Consumables market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.5. Platforms
4.3.1.6. Platforms market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Services
4.4.1. services market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. India oncology NGS: Technology Estimates & Trend Analysis
5.1. India oncology NGS Market: Key Takeaways
5.2. India oncology NGS: Movement & Market Share Analysis, 2022 & 2030
5.3. Whole Genome Sequencing
5.3.1. Whole genome sequence market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Whole Exome Sequencing
5.4.1. Whole exome sequence market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Targeted & Gene Panel Sequencing
5.5.1. Targeted & gene panel sequence market estimates and forecasts, 2018 to 2030 (USD Million)
5.5.2. Amplicon-based
5.5.2.1. Amplicon-based sequence market estimates and forecasts, 2018 to 2030 (USD Million)
5.5.3. Hybridization-based
5.5.3.1. Hybridization-based sequence market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. India oncology NGS: Application Estimates & Trend Analysis
6.1. India Oncology NGS Market: Key Takeaways
6.2. India Oncology NGS: Movement & Market Share Analysis, 2022 & 2030
6.3. Diagnostics and Screening
6.3.1. Diagnostics and screen market estimates and forecasts, 2018 to 2030 (USD Million)
6.3.1.1. Screening
6.3.1.1.1. Screen market estimates and forecasts, 2018 to 2030 (USD Million)
6.3.1.1.2. Sporadic Cancer Screening
6.3.1.1.2.1. Sporadic cancer screen market estimates and forecasts, 2018 to 2030 (USD Million)
6.3.1.1.3. Inherited Cancer Screening
6.3.1.1.3.1. Inherited cancer screen market estimates and forecasts, 2018 to 2030 (USD Million)
6.3.1.2. Companion Diagnostics (CDX)
6.3.1.2.1. Companion diagnostics (CDX)market estimates and forecasts, 2018 to 2030 (USD Million)
6.3.1.3. Other Diagnostics
6.3.1.3.1. Other diagnostics estimates and forecasts, 2018 to 2030 (USD Million)
6.4. Research Studies
6.4.1. Research studies diagnostics estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. India oncology NGS: Workflow Estimates & Trend Analysis
7.1. India Oncology NGS Market: Key Takeaways
7.2. India Oncology NGS: Movement & Market Share Analysis, 2022 & 2030
7.3. Pre-Sequencing
7.3.1. Pre-Sequencing market estimates and forecast, 2018 - 2030 (USD Million)
7.3.1.1. NGS Library Preparation Kits
7.3.1.2. NGS Library Preparation Kits market estimates and forecast, 2018 - 2030 (USD Million)
7.3.1.3. Semi-Automated Library Preparation
7.3.1.4. Semi-automated library preparation market estimates and forecast, 2018 - 2030 (USD Million)
7.3.1.5. Automated Library Preparation
7.3.1.6. Automated library preparation market estimates and forecast, 2018 - 2030 (USD Million)
7.3.1.7. Clonal Amplification
7.3.1.8. Clonal amplification market estimates and forecast, 2018 - 2030 (USD Million)
7.4. Sequencing
7.4.1. Sequencing market estimates and forecast, 2018 - 2030 (USD Million)
7.5. NGS Data Analysis
7.5.1. NGS Data Analysis market estimates and forecast, 2018 - 2030 (USD Million)
7.5.1.1.1. NGS primary data analysis market estimates and forecast, 2018 - 2030 (USD Million)
7.5.1.2. NGS Secondary Data Analysis
7.5.1.2.1. NGS secondary data analysis market estimates and forecast, 2018 - 2030 (USD Million)
7.5.1.3. NGS Tertiary Data Analysis
7.5.1.3.1. NGS tertiary data analysis market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8. India oncology NGS: End-Use Estimates & Trend Analysis
8.1. India Oncology NGS Market: Key Takeaways
8.2. India Oncology NGS: Movement & Market Share Analysis, 2022 & 2030
8.3. Academic Research
8.3.1. Academic research market estimates and forecast, 2018 - 2030 (USD Million)
8.4. Clinical Research
8.4.1. Clinical research market estimates and forecast, 2018 - 2030 (USD Million)
8.5. Hospitals and Clinics
8.5.1. Hospitals & clinics market estimates and forecast, 2018 - 2030 (USD Million)
8.6. Pharma & Biotech Entities
8.6.1. Pharma & biotech entities market estimates and forecast, 2018 - 2030 (USD Million)
8.7. Other Users
8.7.1. Other users market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 9 Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.2.1. Illumina, Inc.
8.2.1.1. Company overview
8.2.1.2. Financial performance
8.2.1.3. Product benchmarking
8.2.1.4. Strategic initiatives
8.2.2. Genotypic Technology Pvt Ltd.
8.2.2.1. Company overview
8.2.2.2. Financial performance
8.2.2.3. Product benchmarking
8.2.2.4. Strategic initiatives
8.2.3. Tecan Trading AG
8.2.3.1. Company overview
8.2.3.2. Financial performance
8.2.3.3. Product benchmarking
8.2.3.4. Strategic initiatives
8.2.4. Xcelris Genomics
8.2.4.1. Company overview
8.2.4.2. Financial performance
8.2.4.3. Product benchmarking
8.2.4.4. Strategic initiatives
8.2.5. Eurofins Scientific
8.2.5.1. Company overview
8.2.5.2. Financial performance
8.2.5.3. Product benchmarking
8.2.5.4. Strategic initiatives
8.2.6. 4baseCare
8.2.6.1. Company overview
8.2.6.2. Financial performance
8.2.6.3. Product benchmarking
8.2.6.4. Strategic initiatives
8.2.7. MedGenome
8.2.7.1. Company overview
8.2.7.2. Financial performance
8.2.7.3. Product benchmarking
8.2.7.4. Strategic initiatives
8.2.8. Sayre Therapeutics
8.2.8.1. Company overview
8.2.8.2. Financial performance
8.2.8.3. Product benchmarking
8.2.8.4. Strategic initiatives
8.2.9. Redcliffe Lifesciences
8.2.9.1. Company overview
8.2.9.2. Financial performance
8.2.9.3. Product benchmarking
8.2.9.4. Strategic initiatives
8.2.10. Partek Inc.
8.2.10.1. Company overview
8.2.10.2. Financial performance
8.2.10.3. Product benchmarking
8.2.10.4. Strategic initiatives
8.2.11. Bio-Rad Laboratories
8.2.11.1. Company overview
8.2.11.2. Financial performance
8.2.11.3. Product benchmarking
8.2.11.4. Strategic initiatives
8.2.12. Myriad Genetics
8.2.12.1. Company overview
8.2.12.2. Financial performance
8.2.12.3. Product benchmarking
8.2.12.4. Strategic initiatives
8.2.13. Hologic, Inc. (Gen-Probe Inc.)
8.2.13.1. Company overview
8.2.13.2. Financial performance
8.2.13.3. Product benchmarking
8.2.13.4. Strategic initiatives
8.2.14. Perkin Elmer, IncVela Diagnostics
8.2.14.1. Company overview
8.2.14.2. Financial performance
8.2.14.3. Product benchmarking
8.2.14.4. Strategic initiatives
8.2.15. Premas Life Sciences Pvt Ltd (PLS)
8.2.15.1. Company overview
8.2.15.2. Financial performance
8.2.15.3. Product benchmarking

List of Tables
Table 1 List of abbreviation
Table 2 India oncology NGS market, by product & service, 2018 - 2030 (USD Million)
Table 3 India oncology NGS market, by technology, 2018 - 2030 (USD Million)
Table 4 India oncology NGS market, by application, 2018 - 2030 (USD Million)
Table 5 India oncology NGS market, by workflow, 2018 - 2030 (USD Million)
Table 6 India oncology NGS market, by end use, 2018 - 2030 (USD Million)

List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 India oncology NGS: Market outlook
Fig. 9 India oncology NGS: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 India oncology NGS market driver impact
Fig. 15 India oncology NGS market restraint impact
Fig. 16 India oncology NGS market strategic initiatives analysis
Fig. 17 India oncology NGS market: Product & service movement analysis
Fig. 18 India oncology NGS market: Product & service outlook and key takeaways
Fig. 19 Platforms and related products market estimates and forecasts, 2018 - 2030
Fig. 20 Panels market estimates and forecasts, 2018 - 2030
Fig. 21 Consumables market estimates and forecasts, 2018 - 2030
Fig. 22 Platforms market estimates and forecasts, 2018 - 2030
Fig. 23 Services market estimates and forecasts, 2018 - 2030
Fig. 24 India oncology NGS market: Technology movement analysis
Fig. 25 India oncology NGS market: Technology outlook and key takeaways
Fig. 26 Whole genome sequencing market estimates and forecasts, 2018 - 2030
Fig. 27 Whole exome sequencing market estimates and forecasts, 2018 - 2030
Fig. 28 Targeted & gene panel sequencing market estimates and forecasts, 2018 - 2030
Fig. 29 Amplicon-based market estimates and forecasts, 2018 - 2030
Fig. 30 Hybridization-based market estimates and forecasts, 2018 - 2030
Fig. 31 India oncology NGS market: Application movement analysis
Fig. 32 India oncology NGS market: Application outlook and key takeaways
Fig. 33 Diagnostic and screening market estimates and forecasts, 2018 - 2030
Fig. 34 Screening market estimates and forecasts, 2018 - 2030
Fig. 35 Companion diagnostics market estimates and forecasts, 2018 - 2030
Fig. 36 Others diagnostics market estimates and forecasts, 2018 - 2030
Fig. 37 Research studies market estimates and forecasts, 2018 - 2030
Fig. 38 India oncology NGS market: Workflow outlook and key takeaways
Fig. 39 India oncology NGS market: Workflow outlook and key takeaway
Fig. 40 Pre-sequencing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 NGS library preparation kits market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Semi-automated library preparation market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Automated library preparation market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Clonal amplification market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Sequencing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 NGS Data analysis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 NGS primary data analysis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 NGS secondary data analysis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 NGS tertiary data analysis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 India oncology NGS market: End-use outlook and key takeaways
Fig. 51 India oncology NGS market: End-use outlook and key takeaway
Fig. 52 Academic Research market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Clinical Research market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 Hospitals & Clinics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Pharma & Biotech Entities market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 56 Other users market estimates and forecast, 2018 - 2030 (USD Million)